Exercise and mind-body interventions for cancer-related fatigue: A network meta-analysis with exploratory moderator analyses.

Complement Ther MedJun 3, 2026 (epub)
Clinical ResearchOncology (Medical)

Jingyi Xie, Zhide Liang, Mengyao Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis evaluated the effectiveness of various exercise and mind-body interventions for cancer-related fatigue (CRF) in 12,629 participants across 205 trials. The findings indicate that these interventions are associated with greater reductions in CRF compared to control conditions, with aquatic exercise showing a standardized mean difference of g = -0.59.

Key findings

  • Exercise and mind-body interventions were associated with greater reductions in CRF than control conditions.
  • Aquatic exercise had a standardized mean difference of g = -0.59.
  • Relaxation training and dance also showed significant reductions in CRF with g = -0.49 and g = -0.47, respectively.
  • No clear optimal dose or threshold for intervention effectiveness was identified.

Why it matters

Understanding the effectiveness of various interventions for cancer-related fatigue is crucial for developing supportive care strategies. This evidence can guide clinicians in recommending appropriate exercise and mind-body therapies tailored to individual patient needs.

Source

PubMed · PMID 42242401

Published in Complement Ther Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.